EBITDA stood at Rs 271 crore in Q1 FY24, up 22% as against Rs 222 crore posted in corresponding quarter last year. EBITDA margin was at 26% during the quarter.

During the quarter, total branded generic sales was up 6% to Rs 732 crore as compared with Rs 688 crore posted in Q1 FY23.

In quarter ended 30 June 2023, revenue from India stood at Rs 319 crore (up 14% YoY ), revenue from Asia was at Rs 254 crore (up 6% YoY) and revenue from US stood at Rs 213 crore (up 19% YoY) while revenue from Africa stood at Rs 168 crore (down 5% YoY).

During Q1 FY24, R&D expenses were Rs 55 crore, which is 5% of revenue from operations. R&D expenses were Rs 77 crore in Q1 FY23.

Meanwhile, the board has approved first interim dividend of Rs 25 per share for FY 2024 and record date for this payout will be Friday, 4 August 2023.

Ajanta Pharma is a specialty pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa.

The scrip hit an all time high at Rs 1,735.10 in intraday today.